Skip to main content
Premium Trial:

Request an Annual Quote

Roche-Illumina News Takes Over Twitter

When Roche yesterday announced its $5.7 billion hostile takeover bid for Illumina, reactions on Twitter were varied and swift, ranging from the humorous — like Stuart Glenn's depiction of what a potential acquisition might be like — to the concerned — "If Roche plans to do to DNA sequencing what it did to PCR, then a lot of genomicists are going to need second jobs," Misha Angrist says — to the optimistic — "More evidence that big pharma is getting ready for personalised med?" James Gazzard asks of the potential deal. Dan Vorhaus summarizes the news simply, tweeting that the "message coming out of Roche seems heavily focused on Dx [diagnostics] development [and] access, not so much technology development."

As our sister publication GenomeWeb Daily News reports, Illumina's board of directors has responded to Roche's bid by adopting a poison pill provision. According to GWDN, Illumina made this move in order to deter what it called "coercive and otherwise unfair takeover tactics" on the part of Roche.

In response to this most recent news, Peter Roberts tweets: "Interesting to see [how] this fight is developing!"

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.